Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required)
Research grant to develop and test new psychosocial interventions for mental disorders, with focus on experimental therapeutics to translate basic science into treatments.
Funder: National Institutes of Health
Due Dates: June 17, 2025 | October 17, 2025 | February 19, 2026 | June 15, 2026 | October 15, 2026 | February 17, 2027 | June 15, 2027 | October 15, 2027
Funding Amounts: No budget cap; up to 2 years for R61 phase and up to 3 years for R33 phase (max 5 years total); budgets must reflect actual project needs.
Summary: Supports pilot clinical trials to develop and test novel psychosocial therapeutic or preventive interventions for mental disorders, emphasizing experimental therapeutics and target engagement.
Key Information: Clinical trial is required; both R61 and R33 phases must be proposed in a single application; foreign and domestic applicants eligible.
Description
This opportunity, issued by the National Institute of Mental Health (NIMH), supports phased, milestone-driven pilot clinical trials to develop and test innovative psychosocial interventions for the prevention or treatment of mental disorders. The focus is on translating basic, behavioral, cognitive, affective, and neuropsychological research into novel interventions, using an experimental therapeutics approach. Projects must propose both an R61 (exploratory) and R33 (replication/extension) phase within a single application, with the R33 phase contingent on meeting predefined milestones in the R61 phase.
The program is designed to accelerate the development of interventions that target novel mechanisms or processes underlying mental disorders, including behavioral, cognitive, affective, interpersonal, or neurobiological factors. Both standalone interventions and augmentations to existing treatments are eligible, provided the target or strategy is novel.
